Skip to main content
Industry News
Combo treatment may benefit youths with B-cell NHL

Children and teens with high-grade, high-risk, mature B-cell non-Hodgkin lymphoma who received rituximab in addition to standard lymphomes malins B chemotherapy had 93.9% three-year progression-free survival, compared with 82.3% among those who were given chemotherapy alone, researchers reported in The New England Journal of Medicine. The findings also showed that 95% of those who received the treatment combo achieved long-term complete remission.

Full Story: